

HER-3 Knocking Down Induces G2/M Arrest in Gastric Cancer Cells

Ehsan Mokhtari¹, Hesamodin Mokhtari², and Elham Moslemi^{1*}

1. Department of Biology, Faculty of Biological Sciences, Islamic Azad University, East Tehran Branch, Tehran, Iran
 2. International Campus, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

Abstract

Background: The Human Epidermal growth factor Receptor-3 (HER-3) is a member of ErbB receptor family and has deficient kinase activity. HER-3 should heterodimerize with other members of ErbB receptor family, especially with HER-2, to transduce downstream signaling pathways. HER-3 co-expresses with other ErbB receptors in different cancers and overexpresses while the oncogenic signaling pathways such as Jak/Stat, MAPK, and PI3K/Akt are activated and promoted. Here, the expression level of HER-3 was evaluated in Iranian gastric adenocarcinoma's patients and the effects of HER-3 knocking down was investigated on cell cycle and cell viability of human gastric adenocarcinoma cell line of MKN45.

Methods: In this study, 38 paraffin-embedded surgical adenocarcinoma specimens and their marginal non-tumor tissue samples were collected. Total RNAs were extracted and cDNAs were synthesized. Finally, the expression level of HER-3 was evaluated by real time PCR approach. Moreover, the human adenocarcinoma cell line of MKN45 was transfected with siRNA against HER-3 and the effects of its down-regulation were evaluated using MTT assay and cell-cycle analysis.

Results: The data obtained from this study revealed HER-3 is significantly overexpressed in gastric tumors rather than non-tumor marginal tissues. Also, it was found that the expression level of HER-3 is elevated with tumor depth of invasion. Moreover, HER-3 knocking down promotes cell accumulation in G2/M phase of cell cycle and decreases cell viability in MKN45 cells which suggests a potential role for HER-3 in gastric adenocarcinoma tumorigenesis.

Conclusion: Taken together, these results emphasize the importance of HER-3 receptor in diagnosis and prognosis of gastric adenocarcinoma.

Avicenna J Med Biotech 2018; 10(4): 227-232

Keywords: Epidermal growth factor receptor, Gastric adenocarcinoma, HER-3, Iran

Introduction

The human Gastric Cancer (GC) is the fourth most commonly diagnosed cancer and the second most common cause of cancer related death worldwide^{1,2}. Gastric carcinogenesis has been known to be a multistep and multifactorial process. Recent advances in molecular medicine have not only shed light on the carcinogenesis of gastric cancer, but also offered novel approaches regarding prevention, diagnosis and therapeutic intervention³. Recently, HER-3, a member of receptor tyrosine kinases, has been introduced as a new biomarker in diagnosis and prognosis of gastric cancer in human⁴.

The human Epidermal Growth Factor Receptor (EGFR) is the most studied family of Receptor Tyrosine Kinases (RTKs) that have important roles in signal transduction and carcinogenesis⁵. ErbB receptors are transmembrane receptors consisting of four proteins

including HER1/EGFR/ErbB1, HER2/ NEU/ErbB2, HER-3/HER-3 and HER4/ErbB4⁶.

Two mechanisms promote receptor dimerization including direct binding of ligands and high receptor density due to overexpression⁷. There is a large number of EGFR ligands that drive the receptor homo- or heterodimerization⁸. HER-3 lacks intrinsic tyrosine kinase activity and it is unable to trigger downstream signaling pathways on its own⁹. Therefore, HER-3 dimerizes with other ErbB receptors, specifically with HER-2 to become activated¹⁰.

Of all the dimers formed by members of the ErbB receptor family, HER-2/HER-3 heterodimers are the most preferable activators of downstream signaling^{10,11}. The importance of HER-2 receptor in some cancers such as breast and gastric cancers has been verified in a lot of recent studies, whereas there are few

* Corresponding author:
 Elham Moslemi, Ph.D.,
 Department of Biology, Faculty
 of Biological Sciences, Islamic
 Azad University, East Tehran
 Branch, Tehran, Iran
 Tel/Fax: +98 9123355872,
 +98 21 88194061
 E-mail:
 Elham_moslemi60@yahoo.com
 Received: 14 Mar 2017
 Accepted: 7 Aug 2017

reports focused on HER-3 as a significant factor involved in carcinogenesis¹². HER-3 is widely expressed in brain, prostate, kidney, lung, spinal cord and mammary glands and its expression is about 50% higher in cancer cells in comparison with normal cells¹³. There are new evidences indicating that HER-3 overexpression is related to tumor size and increased metastasis¹⁴. New researches focused on molecular mechanisms of function of HER-3 in carcinogenesis¹³. The elevated expression of HER-3 confers chemo drug resistance in HER-2+ breast cancer cells through activation of PI-3 K/Akt signaling pathway^{15,16}. All of the mentioned evidences imply the important role of HER-3 receptor in tumor initiation and progression, and also chemo-resistance¹⁴. Some recent studies considered that HER-3 is highly expressed in gastric cancer. It is believed that inhibition of HER-3 signaling with new recombinant drugs may be necessary to overcome chemo-resistance and efficient cancer treatment¹⁷. Therefore, considering the importance of HER-3 in tumorigenesis, an attempt was made to evaluate the expression level of *HER-3* gene in Iranian populations suffering from gastric cancer. In addition, HER-3 was knocked down by siRNA in human gastric cancer cell line of MKN45 and its effects on cell cycle and cell viability were evaluated by flow cytometry and MTT assay, respectively.

Materials and Methods

Clinical samples collection

Human tumor and marginal non-tumor (normal tissues obtained from the margin of same tumors were used as controls) paraffin-embedded surgical specimens from 38 patients with gastric cancer specimens were kindly provided by Masoud Pathobiology Laboratory (Tehran, Iran). Twenty-six samples belonged to males and twelve samples were for females. Patients' ages were in the range between 31 to 73 years old with average age of 54. According to tumor location, 22 samples were non-cardia and 16 samples were cardia tumor and based on grade of differentiation, the low, intermediate and high grades were 11, 13, and 14, respectively (Table 1). The stages and grades were confirmed with histopathological parameters according to WHO criteria.

Cell culture

MKN45, a human gastric adenocarcinoma cell line, was provided by Pasteur Research Institute of Tehran, Iran. Cells were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal calf serum, 100 U/ml penicillin and 100 U/ml streptomycin (Gibico, CA) and incubated at 37°C with 5% CO₂.

RNA extraction and cDNA synthesis

4 to 6 sections (each section in the size of 10 μm) were prepared for each block of paraffinized specimen by microtome. Xylene and alcohol were used for deparaffinization and tissues were treated with proteinase

Table 1. Pathological characteristics of patient's sample

Clinical characteristic	Number of patients
All patients	38
Gender	
Male	26
Female	12
Age (range)	31-73 (51)
Depth of invasion	
T1-T2	11
T3-T4	27
Grade of differentiation	
Low	11
Intermediate	13
High	14
Tumor location	
Cardia	16
Non-cardia	22

K (Fermentase, Lithuania). Each pellet was separately treated with RNase plus solution (CinnaGen, Iran) according to the instruction of manufacturer. Quality and quantity of extracted RNAs were evaluated by UV spectrophotometry (260/280 nm ratio). RNAs were treated with DNaseI (Fermentase, Lithuania) to eliminate any unwanted DNA contamination. The first strand of cDNAs was synthesized using the reverse transcription system (TaKaRa, Japan). Non-reverse transcription (No-RT) control samples were acquired simultaneously from DNase treated RNA to find out any potential genomic DNA contamination.

siRNA and cell treatment

HER-3 siRNA duplexes were synthesized by Qiagen (Valencia, CA, USA). The targeted sequences (sense strand) were as follows: *HER-3*: 5'-AACCAATACCA GACTGTAC-3'. For most experiments, approximately 2×10⁵ cells were plated in six-well plates in medium containing 10% FCS and cultured for 24 hr and then 75% confluence cells were transfected with siRNA using Lipofectamine 2000 (Invitrogen, Paisley, UK) as recommended by manufacturer's instruction. The cells were harvested 0, 24, 48, and 72 hr after transfection by siRNA.

Real-time PCR assay

The expression level of *HER-3* gene in tumor and marginal non-tumor samples was investigated by specific *HER-3* primers: F; 5'-AGTGAGGCCAAGAC TCCAAT-3', R; 5'-ACTCCCAAAGTGTACACCA-3'. Also, *GAPDH* gene was used as an internal control and its primer sequences were as follows: *GAPF*; 5'-A TGGAGAAGGCTGGGGCT-3' and *GAP R*; 5'-ATCT TGAGGCTGTTGTCATACTTCTC-3'.

Quantitative real time PCR was performed with SYBR green master mix based on manufacturer's instruction. The PCR program was as follows: initial denaturation at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 10 s, and annealing/ extension at 60°C for 30 s. The PCR product size verified by

running on agarose gel and the authenticity of amplified fragment were confirmed by direct sequencing of PCR product.

MTT assay

MNK45 cells were seeded at a density of 4×10^3 cells/well on a 96-well plate. After transfection with siRNA against HER-3 and scrambling, viability of cells was investigated after 48, 72 and 96 hr by MTT assay. MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] was added to each well at a concentration of 500 $\mu\text{g/ml}$, and plates were incubated for 4 hr at 37°C. Then, supernatants were removed and cells were lysed with 400 μl DMSO. Cells were incubated further for 10 min at 37°C with gentle shaking. Absorbance was measured at 570 nm using a computer-controlled microplate analyzer.

Cell cycle analysis

Cells were seeded in 6 well plates with density of 2×10^5 cells/well and incubated at 37°C overnight. Then, cells were transfected with HER-3 siRNA, scrambled and incubated for 48 hr. Transfected cells were harvested and fixed by 70% cold ethanol at 4°C overnight and further analyzed by flow cytometry using PI/RNase staining buffer for cell cycle analysis. Distribution of cells in various cell phases was analyzed by Flowing Software 2.5.1.

Western blotting analysis

After siRNA treatment, MNK45 cells were lysed in 1 ml lysis buffer composed of 50 mM Tris-HCL, pH=7.4, 5 mM EDTA, 1% Triton X-100, 150 mM NaCl and 1% protease inhibitor cocktail for 1 hr on ice with 15 min interval of vortexing for 30 s. Using protein assay kit (Bio-Rad Laboratories, CA), the protein concentrations were measured. 30 μg of cell lysates were used for SDS-PAGE. Then, resolved proteins were transferred onto PVDF membrane. Blocking was performed for overnight at 4°C with 5% non-fat milk in PBS plus 0.05% Tween 20. After three times of washing with PBS-Tween with 3% non-fat milk, PVDF membrane was incubated with 5 μg of anti-HER-3 monoclonal antibody (Abcam, Cambridge, UK) for 1 hr at room temperature. After three times of washing with PBS-Tween, membrane was incubated with Horseradish Peroxidase (HRP)- conjugated beta-actin antibody (Abcam, Cambridge, UK) for 1 hr at room temperature followed by washing and developing with ECL chemiluminescence detection system (Pierce ECL Substrate Western blot detection system, Thermo Scientific, IL) and was exposed to autoradiography film (Kodak XAR film).

Statistical analysis

To calculate relative expression of HER-3 in patients, $2^{-\Delta\Delta C_t}$ formula was used. Differences in gene expression between two groups in each analysis were evaluated using one-sample t-test which was performed by SPSS ver. 20 and histograms drawn using Graph Pad Prism 6 Demo software package. The results are

expressed as mean \pm SE of at least triplicate independent experiments. Comparisons between two groups were performed by Mann-Whitney U test. The comparison of HER-3 expression between various clinical characteristics was analyzed by the chi-square test. A p-value less than 0.05 was considered statistically significant.

Results

HER-3 is overexpressed in human gastric adenocarcinoma

Using specific primers, the expression level of HER-3 was evaluated in tumor and non-tumor marginal tissues and between different grades of gastric adenocarcinoma. The results of this study manifested that HER-3 is expressed in both tumor and non-tumor marginal samples of stomach. However, the level of expression is significantly higher in tumor samples compared to non-tumor marginal samples (p-value=0.01). Moreover, in the tumor group, HER-3 expression was significantly associated with depth of invasion (p-value=0.023) (Figure 1).

HER-3 RNA and protein levels reduced after transfection of siRNA

As described in materials and methods, MKN45 cells were transfected with siRNA against HER-3 and scrambled control. After 72 hr, HER-3 mRNA level was decreased about 80% compared to the scrambled control. Also, it was found that HER-3 protein level was sharply reduced in siRNA transfected cells.

Suppressing HER-3 by siRNA arrested MKN45 cells in G2/M phase of cell cycle

Gastric adenocarcinoma cell line of MKN45 was transfected with siRNA against HER-3 and scrambled control. After staining cells with PI, distribution of cells in various phases of cell cycle was analyzed by flow cytometry. Our data revealed that cells treated with siRNA were accumulated in G2/M phase of cell cycle in comparison with the scrambled control cells. Also, the number of cells in G1 and S phases was decreased in siRNA treated cells (Figure 2).




Figure 1. Real time PCR analysis of HER-3. The expression of HER-3 is up-regulated in gastric tumors compared to the non-tumor marginal samples (p-value=0.01). Moreover, the expression level of HER-3 gene is elevated with tumor depth in gastric adenocarcinoma (p=0.023). Real-time PCR was performed as duplicates for three times for each sample. The expression values were normalized relative to the expression level of GAPDH as a housekeeping gene.




Figure 2. Cell cycle analysis of MKN45 cell lines using flow cytometry. MKN45 cells were treated with *HER-3* siRNA (A1), scrambled (A2) and analyzed by flow cytometry after 48 hr. B) number of cells distributed in different cell cycle phases in cells transfected with siRNA and scrambled. *HER-3* silencing increased cell accumulation in G2/M phase of cell cycle up to 20% compared to the scrambled-treated control cells ($p=0.029$).




Figure 3. Western blotting assay for MKN45 cells. MKN45 cells were transfected with *HER-3* siRNAs and harvested 72 hr after transfection. The cells were lysed and 50 mg of total protein was used for detection of ErbB3 by western blotting. *HER-3* protein level was decreased after treatment with siRNA. Beta-actin was used as internal control of western blot.

***HER-3* down-regulation by siRNA decreased viability of MKN45 cells**

MKN45 cells were transfected with *HER-3* siRNA and prepared for MTT assay after 24, 48 and 72 hr. Our data showed that *HER-3* siRNA significantly decreased MKN45 cell proliferation by 50% after 48 hours (Figures 3 and 4).

Discussion

Gastric adenocarcinoma is an aggressive cancer and remains the fourth most common type of cancer and is the second leading cause of cancer-related death worldwide. Gastric cancer is often diagnosed at an advanced stage. The most common therapy is surgical resection in company with chemotherapy or chemo-radiation in appropriate cases¹⁸. Unfortunately, treatment of ad-




Figure 4. Cell viability analysis of siRNA treated MKN45 cells by MTT assay. MKN45 cells were harvested 24, 48 and 72 hr after ErbB3 siRNA transfection and analyzed by MTT assay. Our results showed that ErbB3 downregulation reduced cell viability by 50%, 48 hr after treatment with siRNA compared to scrambled control (p -value=0.013).

vanced or metastatic gastric cancer has seen little progress and median Overall Survival (OS) in this group remains <1 year¹⁹. Gastric cancer is a heterogeneous disease that demands continued attention and research with regard to prevention, early detection and novel therapeutic options. Therefore, finding specific markers for early diagnosis of this cancer is very important in early treatment and preventing more cancer progress.

The human *HER-3* is detected in tissues such as brain, prostate, mammary gland, lung, spinal cord, kidney, and liver¹³. There are increasing reports for *HER-3* role in onset and development of cancer. *HER-3* can become activated with direct binding of ligands such as Neuregulin-1 (NRG-1) and Neuregulin-2 (NRG-2), but its intrinsic kinase domain is deficient and it is therefore unable to trigger downstream signaling pathways on its own²⁰⁻²². Thus, *HER-3* receptor should dimerize with other ErbB receptors, especially with *HER-2*, to drive downstream signaling pathways. One of the requisites for tyrosine kinase activity of *HER-2* is the contribution of *HER-3* receptor^{14,22}. Several signaling pathways can be activated by hetero-dimerization of *HER-3* with other members of ErbB family including PI3K/Akt, PLC γ /PKC, Jac/Stat and MEK/MAPK. Of all dimers formed by the members of ErbB receptor family, *HER-2/HER-3* heterodimers are the most potent activator of downstream signaling^{14,22}. Interestingly, the cells that lack *HER-3* receptors or only a few of them, cannot proliferate and these anti-proliferative properties resulted from loss of *HER-3* could not be compensated by *HER-1* or *HER-4* partners, which suggests the great importance of *HER-3* in carcinogenesis¹⁰. *HER-2/HER-3* heterodimers induce cell proliferation and inhibit apoptosis mainly by enhancing PI3K/Akt signaling pathway. The PI3K/Akt pathway is involved in survival and activated in many cancers. In fact, direct binding of *HER-3* to PI3K enhances PI3K/Akt pathway induced by *HER-2/HER-3*

heterodimers^{10,20,23}. Recently, the role of HER-3 in primary tumors and acquired resistance of HER-2+ breast cancer cells to chemo drug therapy has attracted serious attentions²⁴. HER-3, as a major cause of treatment failure in chemotherapy, mainly confers its influences through activation of PI3K/Akt signaling pathway²⁵.

Several oncogenic mutations in *HER-3* gene have been detected in gastric and colon cancers that elucidate the role of *HER-3* in development of cancer²⁶. Jeong *et al* detected protein- altering mutations in *HER-3* in 1% of patients with colon cancer²⁷. Jaiswal *et al* identified *HER-3* somatic mutations in 11% of patients with colon cancer and 12% patients with gastric cancer¹². Wang *et al* reported frequent mutations in the *HER-3* gene in 10% of patients with gastric cancer²⁸. Based on a meta-analysis by Chen *et al*, *HER-3* plays an essential role in the clinicopathology and prognosis of gastric cancer²⁹.

All the above mentioned observations suggest that *HER-3* is the most important partner of *HER-2* in *HER-2* positive breast cancer and greater attentions must be paid on its molecular functions in chemo-resistance and carcinogenesis. Since, the overexpression of *HER-3* has been observed in some cancers such as breast and gastric adenocarcinoma, in this study, the expression level of *HER-3* was evaluated in Iranian patients with gastric adenocarcinoma. Obtained data in this study demonstrated that the expression of *HER-3* gene is elevated in gastric tumors compared to non-tumor tissues. Notably, the average expression level of *HER-3* gene was higher in T3-T4 classified tumors. Also, *HER-3* knocking down by siRNA reduced cell viability and accumulated cells in G2/M phase of cell cycle.

Osaki *et al* and Zhang *et al* showed that *HER-3* causes uncontrolled cell cycle by PI3K/Akt signaling pathway^{30,31}. In our results, G2/M arrest occurred in MKN45 cells by silencing of *HER-3*. Accumulation of cells in G2/M phase by *HER-3* siRNA is probably related to the Akt inactivation by decreasing cyclin B1 that is resulted in cell proliferation inhibition.

Our results confirmed Wu *et al*'s results that showed *HER-3* is involved in cell proliferation and viability in gastric cancer cell lines³². Taken together, these findings suggest a potential correlation between *HER-3* expression level and gastric tumor progression and malignancy.

Conclusion

Our study demonstrates the importance of expression level of *HER-3* member for gastric cancer diagnosis and prognosis. This study might provide further insight into the prevention and detection of gastric cancer in early stages in near future.

Acknowledgement

This work was financially supported by Islamic Azad University, East Tehran Branch. The authors

would like to thank Masoud Pathobiology Laboratory for cooperation in gastric tumor sample obtaining. There is no conflict of interest in this study.

References

- Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. *Cancer Epidemiol Biomarkers Prev* 2009;18(6):1688-1694.
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2010;127(12):2893-2917.
- Hu B, El Hajj N, Sittler S, Lammert N, Barnes R, Meloni-Ehrig A. Gastric cancer: classification, histology and application of molecular pathology. *J Gastrointest Oncol* 2012;3(3):251-261.
- Xia W, Lau YK, Zhang HZ, Xiao FY, Johnston DA, Liu AR, et al. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. *Clin Cancer Res* 1999;5(12):4164-4174.
- Hubbard SR, Till JH. Protein tyrosine kinase structure and function. *Annu Rev Biochem* 2000;69:373-398.
- Klapper LN, Kirschbaum MH, Seta M, Yarden Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factors. *Adv Cancer Res* 1999;77:25-79.
- Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. *Oncogene* 2000;19(56):6550-6565.
- Atalay G, Cardoso F, Awada A, Piccart MJ. Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. *Ann Oncol* 2003;14(9):1346-1363.
- Lemmon MA, Schlessinger J. Regulation of signal transduction and signal diversity by receptor oligomerization. *Trends Biochem Sci* 1994;19(11):459-463.
- Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. *Expe Cell Res* 2003;284(1):99-110.
- Amin DN, Sergina N, Ahuja D, McMahon M, Blair JA, Wang D, et al. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. *Sci Transl Med* 2010;2(16):16ra7.
- Jaiswal BS, Kljavin NM, Stawiski EW, Chan E, Parikh C, Durinck S, et al. Oncogenic ERBB3 mutations in human cancers. *Cancer Cell* 2013;23(5):603-617.
- Sithanandam G, Anderson LM. The ERBB3 receptor in cancer and cancer gene therapy. *Cancer Gene Ther* 2008;15(7):413-448.
- Ma J, Lyu H, Huang J, Liu B. Targeting of erbB3 receptor to overcome resistance in cancer treatment. *Mol Cancer* 2014;13:105.
- Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. *Exp Cell Res* 2003;284(1):54-65.
- McDonagh CF, Huhlov A, Harms BD, Adams S, Paragas V, Oyama S, et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic

- unit and inhibits heregulin-induced activation of ErbB3. *Mol Cancer Ther* 2012;11(3):582-593.
17. Lee Y, Ma J, Lyu H, Huang J, Kim A, Liu B. Role of erbB3 receptors in cancer therapeutic resistance. *Acta Biochim Biophys Sin (Shanghai)* 2014;46(3):190-198.
 18. Carcas LP. Gastric cancer review. *J Carcinog* 2014;13:14.
 19. Cervantes A, Roda D, Tarazona N, Roselló S, Pérez-Fidalgo JA. Current questions for the treatment of advanced gastric cancer. *Cancer Treat Rev* 2013;39(1):60-67.
 20. Stern DF. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. *J Mammary Gland Biol Neoplasia* 2008;13(2):215-223.
 21. Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. *Br J Cancer* 2007;97(4):453-457.
 22. Koutras AK, Fountzilias G, Kalogeras KT, Starakis I, Iconomou G, Kalofonos HP. The upgraded role of HER3 and HER4 receptors in breast cancer. *Crit Rev Oncol Hematol* 2010;74(2):73-78.
 23. Green AR, Barros FF, Abdel-Fatah TM, Moseley P, Nolan CC, Durham AC, et al. HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer. *Breast Cancer Res Treat* 2014;145(1):33-44.
 24. Seruga B, Tannock IF. Chemotherapy-based treatment for castration-resistant prostate cancer. *J Clin Oncol* 2011;29(27):3686-3694.
 25. Jathal MK, Chen L, Mudryj M, Ghosh PM. Targeting ErbB3: the new RTK (id) on the prostate cancer block. *Immunol Endocr Metab Agents Med Chem* 2011;11(2):131-149.
 26. Wang Y, Yang H, Duan G. HER3 over-expression and overall survival in gastrointestinal cancers. *Oncotarget* 2015;6(40):42868-42878.
 27. Jeong EG, Soung YH, Lee JW, Lee SH, Nam SW, Lee JY, et al. ERBB3 kinase domain mutations are rare in lung, breast and colon carcinomas. *Int J Cancer* 2006;119(12):2986-2987.
 28. Wang K, Kan J, Yuen ST, Shi ST, Chu KM, Law S, et al. Exome sequencing identifies frequent mutation of ARI-D1A in molecular subtypes of gastric cancer. *Nat Genet* 2011;43(12):1219-1223.
 29. Cao GD, Chen K, Xiong MM, Chen B. HER3, but not HER4, plays an essential role in the clinicopathology and prognosis of gastric cancer: a meta-analysis. *PLoS One* 2016;11(8):e0161219.
 30. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. *Apoptosis* 2004;9(6):667-676.
 31. Zhang Y, Gonzalez RM, Zangar RC. Protein secretion in human mammary epithelial cells following HER1 receptor activation: influence of HER2 and HER3 expression. *BMC Cancer* 2011;11:69.
 32. Wu X, Chen Y, Li G, Xia L, Gu R, Wen X, et al. Her3 is associated with poor survival of gastric adenocarcinoma: Her3 promotes proliferation, survival and migration of human gastric cancer mediated by PI3K/AKT signaling pathway. *Med Oncol* 2014;31(4):903.